Open access
Sep 2026
A bispecific CD3×CD19 antibody for systemic lupus erythematosus: a phase 1 trial
Early-phase studies of deep B cell depletion with anti-CD19 chimeric antigen receptor (CAR) T have produced prolonged, drug-free remission in refractory autoimmune disease. However, CAR T cell therapy requires lymphodepleting chemotherapy, autologous cell manufacturing and specialized infrastructure, limiting reach to...
Jason Xu, Chun-Li Mei, Xin Guan et al.
· Nature Medicine · 0 citations